DrugPatentWatch Database Preview
COREG CR Drug Profile
Which patents cover Coreg Cr, and when can generic versions of Coreg Cr launch?
Coreg Cr is a drug marketed by Smithkline Beecham and is included in one NDA. There are two patents protecting this drug and three Paragraph IV challenges.
This drug has fifty-one patent family members in seventeen countries.
The generic ingredient in COREG CR is carvedilol phosphate. There are thirty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.
Summary for COREG CR
| International Patents: | 51 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 106 |
| Patent Applications: | 4,422 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for COREG CR |
| Drug Sales Revenues: | Drug sales revenues for COREG CR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for COREG CR |
| DailyMed Link: | COREG CR at DailyMed |
Recent Litigation for COREG CR
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| GlaxoSmithKline LLC v. Glenmark Pharmaceuticals Inc., USA | 2014-07-03 |
| GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. | 2014-07-03 |
| FLAMEL TECHNOLOGIES S.A. v. LUPIN LIMITED | 2011-05-04 |
Pharmacology for COREG CR
| Drug Class | alpha-Adrenergic Blocker beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists |
Synonyms for COREG CR
| (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol |
| [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine |
| 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol |
| 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol |
| 102641-EP2270011A1 |
| 102641-EP2272841A1 |
| 102641-EP2275420A1 |
| 102641-EP2298764A1 |
| 102641-EP2298765A1 |
| 102641-EP2301936A1 |
| 107741-96-8 |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)- |
| 72956-09-3 |
| 956C093 |
| AB0008431 |
| AB00639903_10 |
| AB00639903_11 |
| AB00639903_12 |
| AB00639903-07 |
| AB00639903-09 |
| AB1004830 |
| AC-1641 |
| AC1L1E0B |
| AKOS005554967 |
| AN-14749 |
| API0001873 |
| Artist |
| Artist (TN) |
| AX8120145 |
| BBL029064 |
| BC204100 |
| BCP0726000253 |
| BCP23386 |
| BCP9000493 |
| BDBM25759 |
| BG0129 |
| BM 14.190 |
| BM 14190 |
| BM-14-190 |
| BM-14.190 |
| BM-14190 |
| BRD-A10977446-001-04-8 |
| BRD-A10977446-001-05-5 |
| BRD-A10977446-045-01-1 |
| C-21835 |
| C06875 |
| C24H26N2O4 |
| carvedilol |
| Carvedilol (JAN/USAN/INN) |
| Carvedilol [USAN:INN:BAN:JAN] |
| Carvedilol [USAN:USP:INN:BAN:JAN] |
| Carvedilol 1.0 mg/ml in Methanol |
| Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Carvedilol, >=98% (HPLC), solid |
| Carvedilol, European Pharmacopoeia (EP) Reference Standard |
| Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material |
| Carvedilol, United States Pharmacopeia (USP) Reference Standard |
| Carvedilolum |
| Carvedilolum [Latin] |
| CC-25436 |
| CCG-100917 |
| CCG-207952 |
| CHEBI:3441 |
| CHEMBL723 |
| Coreg |
| Coreg (TN) |
| Coropress |
| CPD000449280 |
| CS-1194 |
| CTK3J2232 |
| D00255 |
| DB01136 |
| Dibloc |
| Dilatrend |
| DQ 2466 |
| DQ-2466 |
| DTXSID8022747 |
| EG-P042 |
| Eucardic |
| FT-0603059 |
| FT-0652640 |
| GTPL551 |
| HMS2051N03 |
| HMS2089B09 |
| HMS2093E12 |
| HMS3261E15 |
| HMS3269N11 |
| HMS3393N03 |
| HMS3655O14 |
| HMS3715D15 |
| HSDB 7044 |
| HY-B0006 |
| I06-0064 |
| I06-1477 |
| J10039 |
| KB-75594 |
| KBio2_002145 |
| KBio2_004713 |
| KBio2_007281 |
| KBio3_002323 |
| KBioGR_001252 |
| KBioSS_002145 |
| Kredex |
| KS-00000XRT |
| KS-1037 |
| KSC492E3F |
| L001243 |
| LP00347 |
| LS-121875 |
| MCULE-7944987271 |
| MFCD00864692 |
| MLS000758299 |
| MLS000759508 |
| MLS001424092 |
| MLS006011886 |
| MolPort-003-666-814 |
| NC00167 |
| NCGC00167832-01 |
| NCGC00167832-02 |
| NCGC00167832-03 |
| NCGC00167832-04 |
| NCGC00261032-01 |
| NSC-758694 |
| NSC758694 |
| OGHNVEJMJSYVRP-UHFFFAOYSA-N |
| Pharmakon1600-01504257 |
| PubChem18218 |
| Q-200801 |
| Querto |
| RTR-037608 |
| s1831 |
| SAM001246736 |
| SAM001247021 |
| SB17441 |
| SBI-0206771.P001 |
| SC-13445 |
| SCHEMBL10082334 |
| SCHEMBL13287211 |
| SCHEMBL22293 |
| SK&F-105517 |
| SKF 105517 |
| SMR000449280 |
| SPBio_001885 |
| Spectrum_001665 |
| Spectrum2_001673 |
| Spectrum3_001182 |
| Spectrum4_000636 |
| Spectrum5_001436 |
| SR-01000759289 |
| SR-01000759289-5 |
| SR-01000759289-6 |
| SR-01000759289-9 |
| ST24036957 |
| STK621453 |
| SW197547-3 |
| TL8005080 |
| Tox21_500347 |
| TR-037608 |
| W-5131 |
| Z2786051695 |
Paragraph IV (Patent) Challenges for COREG CR
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| COREG CR | CAPSULE, EXTENDED RELEASE;ORAL | carvedilol phosphate | 022012 | 2008-03-18 |
| COREG CR | CAPSULE, EXTENDED RELEASE;ORAL | carvedilol phosphate | 022012 | 2007-12-21 |
| COREG CR | CAPSULE, EXTENDED RELEASE;ORAL | carvedilol phosphate | 022012 | 2007-11-19 |
US Patents and Regulatory Information for COREG CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COREG CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | Start Trial | Start Trial |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | Start Trial | Start Trial |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COREG CR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2013241450 | Start Trial |
| Japan | 2005506336 | Start Trial |
| China | 1678305 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
